darglitazone has been researched along with Insulin Resistance in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boden, G; Chaiken, RL; Eckert-Norton, M; Gelfand, RA; Lebovitz, HE; Pasmantier, R; Ryan, I | 1 |
| Camirand, A; Marie, V; Rabelo, R; Silva, JE | 1 |
1 trial(s) available for darglitazone and Insulin Resistance
| Article | Year |
|---|---|
Metabolic effects of darglitazone, an insulin sensitizer, in NIDDM subjects.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Fatty Acids, Nonesterified; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Obesity; Thiazoles; Thiazolidinediones | 1995 |
1 other study(ies) available for darglitazone and Insulin Resistance
| Article | Year |
|---|---|
Thiazolidinediones stimulate uncoupling protein-2 expression in cell lines representing white and brown adipose tissues and skeletal muscle.
Topics: Adipose Tissue; Animals; Cell Line; Chromans; Gene Expression Regulation; Hypoglycemic Agents; Insulin Resistance; Ion Channels; Membrane Transport Proteins; Mice; Mitochondrial Proteins; Muscle, Skeletal; Proteins; Rats; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone; Uncoupling Protein 2 | 1998 |